Regulation of voltage-dependent K+ channels by methionine oxidation: effect of nitric oxide and vitamin C  by Ciorba, Matthew A. et al.
Regulation of voltage-dependent K channels by methionine oxidation:
e¡ect of nitric oxide and vitamin C
Matthew A. Ciorbaa, Stefan H. Heinemannb, Herbert Weissbachc, Nathan Brotd,
Toshinori Hoshia;*
aDepartment of Physiology and Biophysics, The University of Iowa, Iowa City, IA 52242, USA
bMax-Planck-Gesellschaft, Research Unit Molecular and Cellular Biophysics, Drackendorfer Str. 1, D-07747 Jena, Germany
cDepartment of Biological Sciences, Florida Atlantic University, Boca Raton, FL 33431, USA
dHospital for Special Surgery, Cornell University Medical Center, New York, NY 10021, USA
Received 9 November 1998; received in revised form 17 November 1998
Abstract Methionine oxidation is known to alter functional
properties of a transient A-type potassium channel expressed in
Xenopus oocytes. We show here that nitric oxide (NO) slows
down the K+ channel inactivation time course by oxidizing a
critical methionine residue in the inactivation ball domain of the
channel protein. We also demonstrate that the channel protein is
protected from methionine oxidation by the enzyme methionine
sulfoxide reductase and the antioxidant vitamin C.
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1. Introduction
Functional properties of many proteins are post-transla-
tionally modi¢ed in a variety of ways. Phosphorylation/de-
phosphorylation markedly alters protein activity and its in-
volvement in numerous cellular signal transduction cascades
is well documented. Oxidation of amino acid residues is also
known to a¡ect protein function and protein oxidation has
been implicated in many physiological processes. Although all
amino acids can be oxidized, the oxidization of cysteine and
methionine occurs reversibly, suggesting a possible regulatory
role in cellular processes. In the case of methionine, the thiol
ether group can be reversibly oxidized to methionine sulfoxide
(Met(O)), decreasing the side chain £exibility and increasing
hydrophilicity [1,2]. Reduction of Met(O) in proteins back to
methionine is unique in that the reaction is speci¢cally cata-
lyzed by an enzyme, peptide methionine sulfoxide reductase
(MsrA) [3,4], which has been cloned from bacteria [5], plants
[6], and bovine adrenal gland [4]. MsrA is present in many
organs including brain, kidney, and retina [7]. The observa-
tion that reduction of Met(O) to methionine in proteins is
enzymatically controlled by MsrA suggests that methionine
oxidation/reduction could act as a cellular regulatory mecha-
nism.
Physiological roles of methionine oxidation and reduction
mediated by MsrA have been suggested in several di¡erent
systems. The oxidation of a single methionine residue of
K1-proteinase inhibitor destroys its ability to inactivate elas-
tase and is thought to contribute to smoking-induced emphy-
sema [8] and adult respiratory distress syndrome [9]. The in-
active oxidized protein can be reactivated when incubated
with MsrA [9,10]. Cataract formation may also involve me-
thionine oxidation since about 45% of the methionine residues
in lens proteins are oxidized [11,12]. DNA binding of a Dro-
sophila protein is regulated by methionine oxidation [13] and
the conformational stability of calmodulin is also in£uenced
by methionine oxidation [14]. Previous studies using MsrA-
de¢cient Escherichia coli and yeast strains suggest that MsrA
may function as a ROS defense mechanism [15,16]. In a pre-
vious paper [17], using a heterologous expression system we
demonstrated that methionine oxidation/reduction functions
as a regulator of voltage-dependent A-type K channels.
We showed that N-type inactivation mediated by the ball
and chain mechanism in the ShC/B channel is slowed when
a critical N-terminal methionine (amino acid 3) is oxidized to
Met(O) and that coexpression of MsrA enhances the inacti-
vation process by promoting the reduction of Met(O) to me-
thionine.
Oxidation of methionine to Met(O) can be induced by
many biologically synthesized free radical species with un-
paired electrons, including hydrogen peroxide, hydroxyl radi-
cals, hypochlorous acid, and chloramines [1]. These free rad-
icals are thought to play crucial roles in oxidative stress and
tissue injury. Nitric oxide (NO) and its related species are
involved in regulation of many di¡erent physiological proc-
esses such as vascular tension, synaptic transmission, macro-
phage function and apoptosis [18]. In addition, NO has been
suggested to contribute to methionine oxidation either directly
or indirectly through other free radical species. Some neuro-
toxic e¡ects of NO may be mediated by the oxidant peroxy-
nitrite (ONOO), which is formed by the reaction of NO with
the superoxide anion (O3c2 ) [19,20]. ONOO in turn has been
shown to oxidize methionine to Met(O) in K1-proteinase in-
hibitor [21]. Biosynthesis of NO is mediated by NO synthase
(NOS) from L-arginine [22] and it is present in at least three
di¡erent isoforms, nNOS, eNOS, and iNOS [23].
In this study, we used the ShC/B voltage-dependent K
channel expressed in Xenopus oocytes as a model system to
examine which NO cellular signals could regulate oxidation of
methionine. Since oxidation of a critical methionine residue to
Met(O) in the N-terminus of the ShC/B channel slows down
the inactivation process [17], we hypothesized that any treat-
ment that generates oxidants capable of oxidizing methionine
to Met(O) should slow down the inactivation time course and
that MsrA and antioxidant agents should accelerate the inac-
tivation time course.
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2. Materials and methods
2.1. Expression in oocytes
The ShC/B and ShB channels were expressed in Xenopus oocytes by
RNA injection as described [17]. Each oocyte was injected with about
40 nl of the RNA solution diluted to give the desired expression levels
and incubated in a modi¢ed ND96 solution (96 mM NaCl, 15 mM
KCl, 1 mM MgCl2, 1.8 mM CaCl2, 5 mM HEPES, 2.5 mM Na
pyruvate, 0.5% penicillin/streptomycin, pH 7.6). The rat nNOS
cDNA [24] was linearized with XbaI and the RNA was synthesized
using T7 polymerase (Ambion, Austin, TX, USA). The NOS activity
was assayed as described [25]. The oocytes were incubated at 17‡C in
the dark.
2.2. Electrophysiology
Whole-oocyte currents were recorded using a two-electrode voltage-
clamp ampli¢er (OC725B, Warner Instrument, Hamden, CT, USA).
When ¢lled with 3 M KCl, the electrode resistances were 0.3^0.8 M6.
Macro-patch data were obtained using an AxoPatch 200B ampli¢er
(Axon, Foster City, CA, USA) in the inside-out con¢guration. The
output of the ampli¢er was digitized using an ITC-16 (Instrutech, Port
Washington, NY, USA) attached to an Apple Macintosh computer.
The data acquisition and analysis were performed using PULSE/PULSE-
FIT (HEKA, Lambrecht, Germany) and IGORPRO (WaveMetrics, Lake
Oswego, OR, USA). Leak and capacitative currents were subtracted
using the P/n protocol as implemented in PULSE. The external solution
contained (in mM): 132 NaCl, 10 KCl, 2 CaCl2, 10 HEPES (N-meth-
ylglucamine), pH 7.2. The internal solution in the excised patch ex-
periments contained (in mM): 140 KCl, 11 EGTA, 2 MgCl2,
10 HEPES (N-methylglucamine), pH 7.2. Experiments were typically
performed 1^2 days after RNA injection at room temperature.
Statistical comparisons were made using the results obtained from
the same batch of oocytes and they are given as mean þ S.E.M.
2.3. Reagents
ONOO was synthesized according to the protocol provided by the
University of Iowa Free Radical Research Institute, which is derived
from that by Beckman et al. [26]. The synthesized ONOO was ¢ltered
and concentrated by placing at 320‡C. The concentration was esti-
mated by measuring the absorbance in the 250^300 nm range. For
some experiments, peroxynitrite was also purchased from Calbiochem
(San Diego, CA, USA).
DEANO [27] was obtained from Molecular Probes (Eugene, OR,
USA) and NOR-3 [28] was obtained from ICN (Costa Mesa, CA,
USA). To examine the e¡ects of DEANO or NOR-3, the oocytes
were typically incubated in the presence of the drug (0.5 mg/ml
DEANO; 2 mg/ml NOR3) for 1 h in an air-tight container in the
ND96 solution aerated with O2 and CO2 (95%/5%). The control cells
were incubated in the similarly aerated ND96 without any drug for
1 h. After the incubation, the cells were allowed to recover in fresh
ND96 for 1^2 h before data collection. The incubation in the aerated
ND96 solution alone did not induce any noticeable change in the
measured ShC/B channel properties.
Antioxidant vitamins, vitamin C (L-ascorbic acid), vitamin A (syn-
thetic trans-L-carotene), and vitamin E ((+)-N-tocopherol acetate) were
obtained from Sigma (St. Louis, MO, USA). Cells were incubated in
the presence of 10 mM ascorbic acid. To maintain the proper osmo-
larity, ascorbic acid (10 mM) replaced the equimolar NaCl in the
ND96 solution so that the ¢nal Na concentration in the cell incubat-
ing solution was 86 mM. Cells were incubated in the vitamin A or E
solution overnight. Vitamins A and E were dissolved in a solution
containing approximately 97% ethanol and 0.025% Triton NP-40 and
mixed with a vortex. The ¢nal concentrations of ethanol and Triton in
the ND96 solution were 1.5% and 0.004%, respectively.
3. Results and discussion
3.1. Peroxynitrite slows the inactivation time course of the
ShC/B channel
N-type inactivation of the ShC/B channel is regulated by
the oxidation of one methionine residue at position 3 in the
N-terminus (M3) of the protein [17]. When this methionine is
oxidized to Met(O), the inactivated state becomes unstable,
producing the slow exponential component in the macro-
scopic inactivation time course. Peroxynitrite (ONOO) has
been implicated in mediating protein modi¢cation during re-
perfusion injury [29], and it has been postulated that it pro-
motes methionine oxidation [1,30] especially at low CO2 con-
centrations [30]. Thus, we examined whether ONOO could
oxidize M3 in the ShC/B channel to slow the inactivation
time course. If ONOO promotes methionine oxidation, the
inactivation time course of the ShC/B channel should become
slower. Fig. 1A shows the ShC/B channel inactivation before
and after addition of ONOO directly to the patch. The
ONOO addition to the patch markedly slowed the inactiva-
tion time course. Systematic investigations of the ONOO ef-
fect on the inactivation time course were di⁄cult as the
ONOO application often resulted in a rapid loss of the tight
seal.
The e¡ect of ONOO to slow the ShC/B inactivation time
course is very likely mediated by its action on the N-terminus
ball domain of the channel. The ShC/B ball peptide, corre-
sponding to the distal N-terminal amino acid sequence of the
ShC/B channel, restores inactivation when applied to the
ShBv6^46:T449V channel that does not normally show
N-type inactivation [17,31]. The peptide is much less e¡ective
in inducing inactivation when M3 is replaced with Met(O)
[17]. We hypothesized that if peroxynitrite promotes methio-
nine oxidation in the N-terminus ball domain, the ONOO-
treated ShC/B peptide should be less e¡ective in inducing in-
activation. The e¡ects of the control and ONOO-treated ShC/
B peptides are compared in Fig. 1B. Consistent with the hy-
pothesis, the inactivation time course of the ShBv6^46:T449V
channel current recorded at +50 mV was markedly slower
with the ONOO-treated peptide than with the control peptide.
These results suggest that ONOO promotes methionine oxi-
dation in the N-terminus of the ShC/B channel to slow down
the inactivation time course.
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Fig. 1. A: Peroxynitrite (ONOO) slows the ShC/B channel inactiva-
tion time course. The ShC/B macroscopic currents were recorded in
the inside-out con¢guration in response to pulses to +50 mV from
the holding voltage of 3100 mV. ONOO (4 mM) was applied to
the patch directly. B: ONOO-treated ShC/B ball peptide (MQMIL-
VAGGSLPKLSS) is not e¡ective in inducing inactivation. Macro-
scopic K currents were recorded from the ShBv6^46:T449V chan-
nels in the inside-out con¢guration at +50 mV. This channel has a
large deletion in the N-terminus to disrupt N-type inactivation and
a point mutation to drastically slow C-type inactivation. The ShC/B
peptide was treated with ONOO (1.5 mM) in the standard internal
solution for 1 h at room temperature and then applied to the cyto-
plasmic side.
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3.2. NO donors slow the inactivation time course of the ShC/B
channel
ONOO is formed when NO reacts with superoxide anion
(O3c2 ). Thus, NO should in turn promote methionine oxida-
tion to slow the inactivation time course of the ShC/B chan-
nel. This hypothesis was tested by examining the e¡ects of NO
donors. The ShC/B K currents recorded from the oocytes
incubated with NO donors were compared with the currents
recorded from the control cells. Fig. 2A shows that DEANO
(0.5 mg/ml), a NO donor with a half-life of 2 min, markedly
slowed the ShC/B channel inactivation time course. Another
NO donor, NOR-3 with a half-life of 40 min, also slowed the
ShC/B inactivation time course (Fig. 2B). Similar e¡ects of
DEANO and NOR-3 were observed using four other batches
of oocytes.
The ShB channel di¡ers from the ShC/B channel only in the
amino-terminus and it does not contain any additional me-
thionine in the ball domain. N-type inactivation of the ShB
channel is not regulated by methionine oxidation [17]. If the
e¡ect of the NO donors to slow the ShC/B inactivation time
course is mediated by methionine oxidation in the N-termi-
nus, these NO donors should not alter the ShB inactivation
time course. Consistent with this prediction, incubation of the
cells expressing the ShB channels with DEANO (0.5 mg/ml)
did not markedly alter the inactivation time course (Fig. 2C;
2-sample t-test, P = 0.65). In some cells, however, greater
steady-state currents were observed, suggesting that the NO
donors may have other targets. The di¡erential e¡ects of NO
donors on the ShB and ShC/B channels suggest that NO slows
the ShC/B inactivation time course by promoting methionine
oxidation in the N-terminus.
MsrA catalyzes reduction of Met(O) to methionine [3,4].
We showed previously that MsrA can accelerate the inactiva-
tion time course of the ShC/B channel by promoting reduction
of Met(O) to methionine at position 3 in the ball domain [17].
We hypothesized that MsrA should protect the channel from
the oxidizing in£uence of DEANO. Thus, we compared the
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Fig. 3. NOS coexpression slows the ShC/B channel inactivation time
course. A: Average scaled whole-oocyte currents recorded from the
cells injected with the ShC/B RNA only and from the cells injected
with the ShC/B and nNOS RNAs together. The currents were re-
corded from 11 cells in each group in response to pulses to 0 mV.
Line width represents S.E.M. The cells in both the control and the
ShC/B-NOS experimental groups were incubated in the presence of
the Ca2 ionophore A23187 (10 WM) for 1 h and allowed to recover
in ND96 solution for s 2 h before the recording. The mean peak
current amplitudes in the control and coexpression groups were
2.0 þ 0.1 WA and 5.8 þ 1.7 WA, respectively. B: Relative fraction of
the slow inactivation is increased by NOS coexpression. The ShC/B
inactivation time course was ¢tted with a sum of two exponentials
and the relative fraction of the slow component is compared using
boxplots. The shaded areas represent the 95% con¢dence intervals
of the median.
Fig. 2. DEANO and NOR-3 slow the time course of the ShC/B
channel inactivation. A: Whole-oocyte currents recorded at +30 mV
from seven cells in the control group (light sweeps) and six cells in
the DEANO-incubated group (dark sweeps) are scaled and shown
superimposed. The mean peak current amplitudes in the control and
DEANO groups were 5.8 þ 0.4 WA and 3.9 þ 0.7 WA, respectively. B:
Whole-oocyte currents recorded at +30 mV from seven cells before
(light sweeps) and after (dark sweeps) incubation in NOR-3 for 1 h.
The currents from the cells were measured (control), incubated in
the presence of NOR-3 (2 mg/ml) for 1 h, and then measured again.
C: DEANO does not a¡ect the time course of the ShB channel in-
activation. Whole-oocyte currents recorded at +30 mV from eight
cells in the control group (top) and four cells in the DEANO-incu-
bated group (bottom) are scaled and shown. The inactivation time
course was ¢tted with a single exponential and the time constant
values are compared using boxplots (right). The shaded area repre-
sents the 95% con¢dence interval of the median. The average cur-
rents are also shown (right). The mean peak current amplitudes in
the control and DEANO groups were 7.9 þ 1.4 WA and 5.4 þ
1.1 WA, respectively. D: MsrA protects the ShC/B channel from oxi-
dation induced by DEANO. The average whole-oocyte currents re-
corded at +30 mV from the oocytes expressing the ShC/B channels
alone (left) and MsrA and the ShC/B channels together (right) are
compared. In each panel, the currents from the control and
DEANO-incubated groups are compared. The DEANO incubation
protocol is described in Section 2. Each line represents an average
response from s 20 cells and the line width indicates S.E.M. The
mean peak current amplitudes in the ShC/B DEANO, ShC/B con-
trol, ShC/B-MsrA DEANO, and ShC/B-MsrA groups were
13.9 þ 1.2, 7.8 þ 0.8, 7.2 þ 0.8 and 11.7 þ 0.6 WA, respectively.
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e¡ects of DEANO on the oocytes expressing the ShC/B chan-
nels alone and those expressing the channels and MsrA to-
gether. As predicted by the hypothesis, DEANO was much
less e¡ective in slowing the inactivation time course in the
oocytes expressing both the channels and MsrA (Fig. 2D)
than in the oocytes expressing the channels alone, showing
that MsrA can protect the channels from the NO-mediated
oxidative stress. Similar results were observed using two other
batches of oocytes.
3.3. nNOS coexpression slows the inactivation time course of
the ShC/B channel
We further tested whether NO could promote methionine
oxidation to slow the ShC/B channel inactivation time course
by coexpression of the channels with nNOS [24]. Injection of
the nNOS RNA into Xenopus oocytes followed by an incuba-
tion with the Ca2 ionophore A23187 (10 WM; Sigma, St.
Louis, MO, USA) enhanced the NOS activity of the cell ex-
tract by approximately 300% from 50 nmol/mg protein to 155
nmol/mg protein using the method of Xie et al. [25]. The mean
ShC/B K current recorded at +30 mV from the cells injected
with the channel RNA alone and treated with A23187, and
the mean current from the cells injected with the channel and
nNOS RNAs together and treated with A23187 are compared
in Fig. 3. The average inactivation time course was markedly
slower in the cells expressing both the channels and nNOS.
The e¡ect of the nNOS coexpression was speci¢c in that it
selectively enhanced the relative fraction of the slow inactiva-
tion component without markedly altering the time constant
values of the two components (Fig, 3B; 2-sample t-test,
P = 0.06 for the fast time constant value, P = 0.64 for the
slow time constant value and P = 0.0002 for the slow time
constant fraction). The results suggest that the increase in
NOS activity could cause methionine oxidation in the channel
and regulate the ShC/B channel kinetics.
3.4. Vitamin C accelerates the inactivation time course
Since methionine oxidation slows the ShC/B channel inac-
tivation time course, it was hypothesized that antioxidants
should accelerate the ShC/B channel inactivation time course.
We examined the e¡ects of antioxidant vitamin A, vitamin C,
and vitamin E on the ShC/B channel. The mean ShC/B K
currents from the control cells and from the cells incubated
with vitamin C are compared in Fig. 4. Incubation with vita-
min C (10 mM) accelerated the inactivation time course in a
statistically signi¢cant manner. The incubation speci¢cally de-
creased the fraction of the slow inactivation component with-
out a¡ecting the time constant values of the two inactivation
components (2-sample t-test, P = 0.13 for the fast time con-
stant, P = 0.20 for the slow time constant and P = 0.0009 for
the slow component fraction). Incubation with vitamin A or
vitamin E (1 mM) did not produce consistent e¡ects on the
ShC/B K currents (n = 50). Since the N-terminal ball domain
of the Shaker channel is cytoplasmic and these vitamins are
lipid soluble, their inability to regulate the ShC/B channel may
be caused by their preferential distribution in the plasma
membrane away from the ball domain.
3.5. Methionine oxidation as a regulator of
cellular excitability
The results presented show that a variety of treatments,
such as ONOO, NO donors and nNOS coexpression, promote
methionine oxidation and slow the inactivation time course of
the ShC/B channel. Such a role of NO in methionine oxida-
tion has been speculated, but there has been little direct evi-
dence previously to support this idea [1]. It is likely that NO
induces methionine oxidation indirectly via ONOO [1,21].
ONOO is a strong oxidant formed by the reaction of super-
oxide with NO and it is implicated in a variety of tissue and
cellular injury phenomena [32]. The observation that the ShC/
B inactivation time course is slowed by direct application of
ONOO as well as by NO donors and NOS coexpression sug-
gests that ONOO may mediate the action of NO in the ShC/B
channel although other mechanisms cannot be totally ex-
cluded [33]. Furthermore, MsrA protects the ShC/B channel
from slowing of the inactivation time course induced by a NO
donor. The Shaker and NOS proteins could physically inter-
act with the postsynaptic density protein PSD95 via their
PDZ domains [34,35], suggesting that these proteins may pref-
erentially co-localize. A recent study suggests that at low L-
arginine concentrations NOS could also produce superoxide,
leading to formation of ONOO, which then contributes to
cytotoxicity and cellular injury [36]. Although peroxynitrite
has a short half-life under physiological conditions [37], the
potential proximity of the Shaker and NOS proteins may
allow NO-triggered methionine oxidation to serve as an im-
portant regulator of cellular excitability.
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Fig. 4. Vitamin C accelerates the ShC/B channel inactivation time
course. A: Average scaled whole-oocyte currents recorded at 0 mV
from the control cells and the cells incubated with vitamin C. The
currents recorded from 10 cells in the control and 14 cells in the ex-
perimental groups in response to pulses to 0 mV were scaled and
averaged. Line width represents S.E.M. The average currents are
also shown (right). The mean peak current amplitudes in the control
and vitamin C groups were 17.1 þ 2.0 WA and 14.0 þ 2.5 WA, respec-
tively. B: The ShC/B inactivation time course was ¢tted with a sum
of two exponentials and the ¢t parameter values are compared using
boxplots. The shaded areas represent the 95% con¢dence intervals
of the median.
M.A. Ciorba et al./FEBS Letters 442 (1999) 48^52 51
Acknowledgements: We thank Dr. J. Thommandru and Ms. M. Mas-
ropour for technical assistance and F. King for inspiration. This work
was in part supported by HFSP, DFG (He2993) and NIH GM57654.
References
[1] Vogt, W. (1995) Free Radical Biol. Med. 18, 93^105.
[2] Berlett, B.S. and Stadtman, E.R. (1997) J. Biol. Chem. 272,
20313^20316.
[3] Brot, N., Rahman, M.A., Moskovitz, J. and Weissbach, H.
(1995) Methods Enzymol. 251, 462^470.
[4] Moskovitz, J., Weissbach, H. and Brot, N. (1996) Proc. Natl.
Acad. Sci. USA 93, 2095^2099.
[5] Rahman, M.A., Nelson, H., Weissbach, H. and Brot, N. (1992)
J. Biol. Chem. 267, 15549^15551.
[6] Sadanandom, A., Pi¡anelli, P., Knott, T., Robinson, C., Sharpe,
A., Lydiate, D., Murphy, D. and Fairbairn, D.J. (1996) Plant J.
10, 235^242.
[7] Moskovitz, J., Jenkins, N.A., Gilbert, D.J., Copeland, N.G., Jur-
sky, F., Weissbach, H. and Brot, N. (1996) Proc. Natl. Acad. Sci.
USA 93, 3205^3208.
[8] Carp, H., Miller, F., Hoidal, J.R. and Jano¡, A. (1982) Proc.
Natl. Acad. Sci. USA 79, 2041^2045.
[9] Cochrane, C.G., Spragg, R. and Revak, S.D. (1983) J. Clin. In-
vest. 71, 754^761.
[10] Abrams, W.R., Weinbaum, G., Weissbach, L., Weissbach, H.
and Brot, N. (1981) Proc. Natl. Acad. Sci. USA 78, 7483^7486.
[11] Truscott, R.J. and Augusteyn, R.C. (1977) Biochim. Biophys.
Acta 492, 43^52.
[12] Garner, M.H. and Spector, A. (1980) Proc. Natl. Acad. Sci. USA
77, 1274^1277.
[13] Dow, L.K., Changela, A., Hefner, H.E. and Churchill, M.E.A.
(1997) FEBS Lett. 414, 514^520.
[14] Gao, J., Yin, D.H., Yao, Y.H., Sun, H.Y., Qin, Z.H., Schoneich,
C., Williams, T.D. and Squier, T.C. (1998) Biophys. J. 74, 1115^
1134.
[15] Moskovitz, J., Rahman, M.A., Strassman, J., Yancey, S.O.,
Kushner, S.R., Brot, N. and Weissbach, H. (1995) J. Bacteriol.
177, 502^507.
[16] Levine, R.L., Mosoni, L., Berlett, B.S. and Stadtman, E.R.
(1996) Proc. Natl. Acad. Sci. USA 93, 15306^15340.
[17] Ciorba, M., Heinemann, S.H., Brot, N., Weissbach, H. and
Hoshi, T. (1997) Proc. Natl. Acad. Sci. USA 94, 9932^9937.
[18] Beckman, J.S. and Koppenol, W.H. (1996) Am. J. Physiol. 271,
C1424^1437.
[19] Dawson, V.L. and Dawson, T.M. (1996) J. Chem. Neuroanat.
10, 179^190.
[20] Lipton, S.A., Choi, Y.B., Pan, Z.H., Lei, S.Z., Chen, H.S., Such-
er, N.J., Loscalzo, J., Singel, D.J. and Stamler, J.S. (1993) Nature
364, 626^632.
[21] Moreno, J.J. and Pryor, W.A. (1992) Chem. Res. Toxicol. 5,
425^431.
[22] Yun, H.Y., Dawson, V.L. and Dawson, T.M. (1996) Crit. Rev.
Neurobiol. 10, 291^316.
[23] Forstermann, U., Gath, I., Schwarz, P., Closs, E.I. and Kleinert,
H. (1995) Biochem. Pharmacol. 50, 1321^1332.
[24] Bredt, D.S., Hwang, P.M., Glatt, C.E., Lowenstein, C., Reed,
R.R. and Snyder, S.H. (1991) Nature 351, 714^718.
[25] Xie, Q.W., Leung, M., Fuortes, M., Sassa, S. and Nathan, C.
(1996) Proc. Natl. Acad. Sci. USA 93, 4891^4896.
[26] Beckman, J.S., Chen, J., Ischiropoulos, H. and Crow, J.P. (1994)
Methods Enzymol. 233, 229^240.
[27] Maragos, C.M., Morley, D., Wink, D.A., Dunams, T.M., Saave-
dra, J.E., Ho¡man, A., Bove, A.A., Isaac, L., Hrabie, J.A. and
Keefer, L.K. (1991) J. Med. Chem. 34, 3242^3247.
[28] Kita, Y., Hirasawa, Y., Maeda, K., Nishio, M. and Yoshida, K.
(1994) Eur. J. Pharmacol. 257, 123^130.
[29] Awasthi, D., Church, D.F., Torbati, D., Carey, M.E. and Pryor,
W.A. (1997) Surg. Neurol. 47, 575^581.
[30] Berlett, B.S., Levine, R.L. and Stadtman, E.R. (1998) Proc. Natl.
Acad. Sci. USA 95, 2784^2789.
[31] Murrell-Lagnado, R.D. and Aldrich, R.W. (1993) J. Gen. Phys-
iol. 102, 977^1003.
[32] Beckman, J.S. (1996) Chem. Res. Toxicol. 9, 836^844.
[33] Kirsch, M., Lomonosova, E.E., Korth, H.G., Sustmann, R. and
Degroot, H. (1998) J. Biol. Chem. 273, 12716^12724.
[34] Kim, E., Niethammer, M., Rothschild, A., Jan, Y.N. and Sheng,
M. (1995) Nature 378, 85^88.
[35] Brenman, J.E., Chao, D.S., Gee, S.H., McGee, A.W., Craven,
S.E., Santillano, D.R., Wu, Z., Huang, F., Xia, H., Peters, M.F.,
Froehner, S.C. and Bredt, D.S. (1996) Cell 84, 757^767.
[36] Xia, Y., Dawson, V.L., Dawson, T.M., Snyder, S.H. and Zweier,
J.L. (1996) Proc. Natl. Acad. Sci. USA 93, 6770^6774.
[37] Ischiropoulos, H., Zhu, L., Chen, J., Tsai, M., Martin, J.C.,
Smith, C.D. and Beckman, J.S. (1992) Arch. Biochem. Biophys.
298, 431^437.
FEBS 21361 4-1-99
M.A. Ciorba et al./FEBS Letters 442 (1999) 48^5252
